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Background: The aim was to compare percutaneous transluminal angioplasty (PTA), a supervised
exercise programme (SEP) and combined treatment (PTA plus SEP) for intermittent claudication due
to femoropopliteal arterial disease.
Methods: Consenting patients with femoropopliteal arterial lesions were randomized to one of three
treatment arms: PTA, SEP, or PTA plus SEP. All patients received optimal medical treatment. Patients
were assessed at baseline and 1, 3, 6 and 12 months after intervention. Clinical (ankle pressures, walking
distances, symptoms) and quality-of-life (QoL) outcomes (Short Form 36, VascuQol) were analysed.
Results: A total of 178 patients (108 men, median age 70 years) were included. All three treatment
groups demonstrated significant clinical and QoL improvements. One year after PTA (60 patients, 8
withdrew), 37 patients (71 per cent) had improved (16 mild, 16 moderate, 5 marked), nine (17 per cent)
showed no improvement and six (12 per cent) had deteriorated. After SEP (60 patients, 14 withdrew),
32 patients (70 per cent) had improved (19 mild, 10 moderate, 3 marked), six (13 per cent) showed no
improvement and eight (17 per cent) had deteriorated. After PTA plus SEP (58 patients, 11 withdrew),
40 patients (85 per cent) had improved (18 mild, 20 moderate, 2 marked), seven (15 per cent) showed
no improvement and none had deteriorated. On intergroup analysis, PTA and SEP alone were equally
effective in improving clinical outcomes, although the effect was short-lived. PTA plus SEP produced a
more sustained clinical improvement, but there was no significant QoL advantage.
Conclusion: For patients with intermittent claudication due to femoropopliteal disease, PTA, SEP,
and PTA plus SEP were all equally effective in improving walking distance and QoL after 12 months.
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Introduction
Intermittent claudication (IC) is the most common presen-
tation of peripheral arterial occlusive disease (PAD), with
a prevalence of 5–10 per cent in the UK population over
50 years old1. Despite its benign course, with more than
80 per cent of patients remaining stable2, IC confers sig-
nificant quality-of-life (QoL) limitations3, and is a known
risk factor for coronary and cerebrovascular events4,5.
The annual mortality rate approaches 5 per cent, three
times that of an age- and gender-matched population6.
Treatment of patients with claudication has two aims:
to improve QoL7 and to reduce deaths from myocar-
dial infarction and stroke4. Management options for IC
include best medical treatment with risk factor modifi-
cation (BMT), a supervised exercise programme (SEP),
percutaneous transluminal angioplasty (PTA), vasodilator
drugs8 and, occasionally, surgery9.
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PTA is considered the first-line treatment for aortoiliac
artery PAD, with good 5-year patency rates10. However,
in patients with femoropopliteal PAD, the results are less
impressive. Consequently, there is lack of consensus for
treatment of IC in this group11. Supervised exercise is a
well established treatment for IC, with clinical and QoL
benefits. Previous randomized trials comparing SEP and
PTAhave failed to identify a clear clinical benefit for either,
mainly due to the limited number of trial participants12–14.
A Cochrane review identified the possibility of bias in the
previous trials and the need for a larger one to provide
further evidence15. Additionally, previous studies did not
investigate whether combining the two treatments would
be better than either treatment alone. Previous studies
have suggested that improvement in clinical parameters
after treatment for IC may not mirror the change in
QoL16 as assessed using generic and disease-specific
instruments7,17.
This prospective, single-centre, randomized clinical trial
was designed to compare PTA, SEP, and combined
treatment (PTA plus SEP) in patients with IC due to
femoropopliteal arterial disease.
Methods
The study was approved by the local research ethics
committee and conducted in the academic vascular
surgical unit of a university hospital. All patients with
symptomatic unilateral claudication attending vascular
outpatients between September 2002 and April 2007 were
screened to assess their suitability for inclusion in the trial.
Duplex ultrasonography was performed in all suitable
patients to assess the site, nature and extent of any arterial
lesions. The scans were discussed in a weekly vascular
multidisciplinary team meeting. Patients with unilateral
infrainguinal lesions suitable for angioplastywere identified
as potential participants and commencedBMT, comprising
antiplatelet therapy (aspirin and/or clopidogrel), smoking
cessation advice and support (National Health Service
smoking cessation programme, nicotine replacement
therapy), and risk factor modification according to
evidence-based care pathways (goal-oriented management
of diabetes, control of hypertension and treatment of
hypercholesterolaemia) within a dedicated nurse-led clinic.
Patients were also provided with advice leaflets on physical
activity and exercise.
Suitable patients were reassessed after 3 months and
included in the trial if their symptoms remained stable.
Informed consent was obtained from all participants.
Randomization into one of the three treatment arms (PTA,
SEP, or PTA plus SEP) was undertaken at this stage
using sealed envelopes if all inclusion and exclusion criteria
(Table 1) were fulfilled. As recruitment for the study started
before publication of the current Inter-Society Consensus
for the Management of PAD (TASC II) guidelines11,
TASC grading of lesions was undertaken only in retrospect
after completion of recruitment.
Interventions
Percutaneous transluminal angioplasty
PTA was performed by a consultant vascular radiologist
according to a predefined protocol in accordance with
the normal practice of the unit, in a dedicated vascular
radiology suite. Access was gained from the contralateral
side and diagnostic angiographywas performed followed by
balloon angioplasty (repeated if required) and completion
angiography. Adjunctive procedures or stents were not
used in any patient.
Supervised exercise programme
SEP was carried out three times a week for 12 weeks under
the supervision of trained physiotherapists or doctors. The
SEP was designed specifically for claudicants based on the
recommendations of a previous meta-analysis18, and was
tested and validated for clinical and cost effectiveness19.
Patients were required to attend at least 85 per cent
of sessions for successful completion of the SEP. The
programme included closed-circuit training on six stations,
each lasting for 2 min, with 2 min of brisk walking between
each station. Each training session was preceded by gentle
warm-up exercises, and followed by gentle stretching and
cooling down exercises. Patients completed one full circuit
for the first 6 weeks, followed by an additional increment
of one station per week for the next 6 weeks, ultimately
Table 1 Inclusion and exclusion criteria for the trial
Inclusion criteria Exclusion criteria
Symptomatic unilateral intermittent Critical ischaemia
claudication
Femoropopliteal lesion amenable to
angioplasty (as discussed in the
MDT meeting)
Symptoms stable after 3 months on
best medical therapy
Incapacitating systemic
disease
Inability to tolerate treadmill
testing (unrelated to limb
ischaemia)
Significant ischaemic changes
on ECG during treadmill
testing
Ipsilateral vascular surgery
within previous 6 months
Ipsilateral peripheral
angioplasty within previous
6 months
MDT, multidisciplinary team; ECG, electrocardiogram.
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completing two full circuits at 12 weeks. Details of the
six exercise stations are shown in Table S1 (supporting
information).
Combined therapy
Patients in the combined treatment group underwent
PTA according to the protocol described above, with
commencement of SEP a week after the procedure.
Assessments
Patients were assessed at baseline (before intervention)
and at 1, 3, 6 and 12 months after intervention ran-
domization. At each assessment, the patients underwent
fixed-load treadmill testing at 2·5 km/h and 10° incli-
nation, to a maximum of 5 min. Clinical indicators of
lower limb ischaemia, including resting and postexercise
ankle : brachial pressure indices (ABPIs) measured using
an anaeroid sphygmomanometer and a 8-MHz hand-held
Doppler probe (Huntleigh Technology, Cardiff, UK), IC
distance (ICD) and maximum walking distance (MWD) up
to a maximum of 215 m (5 min on treadmill), and patient-
reported walking distance (PRWD, up to a maximum of
1000 m), were recorded.
In addition, duplex ultrasound imaging was performed
at 3 and 12 months in the PTA and PTA plus SEP groups
to assess target vessel patency. Patients also completed the
Short Form 36 (SF-36; QualityMetric, Lincoln, Rhode
Island, USA) and King’s College Vascular Quality of
Life (VascuQol) questionnaires for assessment of generic
and disease-specific QoL respectively. These instruments
have been tested and validated for use in patients with
claudication in numerous previous studies3,17,20.
Outcome measures
Primary outcome measures included MWD, and the
physical function (PF) domain of SF-36 at 12 months.
Secondary outcome measures included clinical indicators
(ABPI, ICD, MWD and PRWD) at all time points,
clinical outcomes at 12 months reported according to the
International Society for Cardiovascular Surgery (ISCVS)
outcome criteria (marked improvement, 3; moderate
improvement, 2; mild improvement, 1; no change, 0;
mild deterioration, −1; moderate deterioration, −2)21,
restenosis and reintervention rates, generic QoL outcomes
reported as SF-36 domain scores and disease-specific
QoL outcomes reported as the VascuQol score at all time
points.
Sample size calculations
Sample size calculations used 80 per cent power and
α = 0·05, giving a K (constant) value of 7·9. Calculations
were performed for all primary and secondary outcome
measures using previously published studies. For example,
for MWD as a primary outcome measure, data from the
Oxford trial paper were used that reported mean(s.d.)
MWD as 120(28) m12. Using these values, 19 patients
were required in each treatment arm to detect a 20 per cent
difference in MWD (25 m). Similar calculations were done
using ABPI, ICD, domain scores of SF-36 and VascuQol.
The largest sample size was calculated using the PF domain
of SF-36. Using a mean(s.d.) PF score of 43(18) from
previously published data22, 50 patients were needed in
each treatment arm to detect a 20 per cent difference.
Anticipating a 20 per cent dropout rate, the aim was to
recruit 60 patients in each treatment arm.
Statistical analysis
Data were recorded in Microsoft Excel 2007 for
Windows (Microsoft, Redmond, Washington, USA)
and analysed using SPSS version 16.0 (SPSS, Chicago,
Illinois, USA) and Stata release 11·0 SE (StataCorp,
College Station, Texas, USA).
Non-parametric statistical tests were used throughout
the study after appropriate testing for normality using
histograms and statistical tests (Kolmogorov–Smirnov
test). Intragroup analysis was performed using the
Friedman test to compare differences over the course of
the study, and the Wilcoxon signed rank test to compare
differences between each pair of time points. Intergroup
analysis was done using Kruskal–Wallis ANOVA for
continuous variables. Categorical variables were analysed
using the χ2 test for trend, Mann–Whitney U test and
Fisher’s exact test as appropriate. Adjustment was made to
P values for multiple testing using the Bonferroni method.
Results
Over a 6-year interval between September 2001 and
December 2007, 1157 patients were assessed for inclusion
in the study; 178 (15·4 per cent) were recruited and
randomized into one of the three treatment arms (PTA,
60; SEP, 60; PTA plus SEP, 58). Thirty-three patients
(18·5 per cent) later withdrew from the study and 145
(PTA, 52; SEP, 46; PTA plus SEP, 47) completed
the 1-year follow-up (Fig. 1). There were no significant
differences in demographics, risk factors (Table 2) or
clinical and QoL indicators at baseline among the three
treatment groups. Retrospective TASC grading scored 80
 2011 British Journal of Surgery Society Ltd www.bjs.co.uk British Journal of Surgery 2012; 99: 39–48
Published by John Wiley & Sons Ltd
42 F. A. K. Mazari, J. A. Khan, D. Carradice, N. Samuel, M. N. A. Abdul Rahman, S. Gulati et al.
En
ro
lm
en
t
An
al
ys
is
Assessed for eligibility n = 1157
Allocated to PTA n = 60
Received PTA n = 60
Did not receive PTA n = 0
Allocated to SEP n = 60
Received SEP n = 51
Did not receive SEP n = 9
Withdrew from SEP n = 9
Allocated to PTA + SEP n = 58
Received PTA + SEP n = 49
Did not receive PTA + SEP n = 9
Withdrew from SEP n = 8
Died before intervention n = 1
Lost to follow-up n = 5
Withdrew from trial without
   giving reason n = 3
Change of residence n = 2
Discontinued intervention n = 0
Analysed n = 46
Excluded from analysis n = 0
Lost to follow-up n = 8
Withdrew from trial without
    giving reason n = 6
Change of residence n = 2
Discontinued intervention n = 0
Analysed n = 52
Excluded from analysis n = 0
Lost to follow-up n = 2
Withdrew from trial without
    giving reason n = 1
Change of residence n = 1
Discontinued intervention n = 0
Analysed n = 47
Excluded from analysis n = 0
Randomized n = 178
Excluded n = 979
Did not meet inclusion criteria n = 585
Bilateral disease n = 119
Aortoiliac disease n = 185
Flush SFA occlusion n = 87
Diffuse SFA disease n = 113
Distal disease n = 81
Declined to participate n = 153
Improved on BMT n = 236
Other reason n = 5
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Fig. 1 CONSORT diagram for the trial. SFA, superficial femoral artery; BMT, best medical therapy; SEP, supervised exercise
programme; PTA, percutaneous transluminal angioplasty
Table 2 Clinical details of patients in the trial
PTA (n = 60) SEP (n = 60) PTA + SEP (n = 58) P‡
Age (years)* 70 (63, 75) 69 (63, 76) 69·5 (64, 79) 1·000§
Sex ratio (M : F) 37 : 23 37 : 23 33 : 25 0·659
Side† 0·103
Right 29 (48) 24 (40) 34 (59)
Left 31 (52) 36 (60) 24 (41)
Risk factors†
Diabetes 8 (13) 9 (15) 8 (14) 0·921
Hypertension 40 (67) 40 (67) 34 (59) 0·561
Hypercholesterolaemia 45 (75) 47 (78) 43 (74) 0·705
Current smoker 18 (30) 18 (30) 19 (33) 0·972
*Values are median (95 per cent confidence interval); †values in parentheses are percentages. PTA, percutaneous transluminal angioplasty; SEP,
supervised exercise programme. ‡χ2 test for trend, except §Kruskal–Wallis ANOVA.
lesions as grade A, 66 as grade B, 23 as grade C and five
as grade D; four results were missing. Proportions were
similar in each treatment group (P = 0·632).
Intragroup analyses
Clinical indicators of lower limb ischaemia
A statistically significant improvement was seen in all
clinical indicators (resting and postexercise ABPI, MWD
and PRWD) at all time points, including the final endpoint
at 1 year in all three treatment arms except postexercise
ABPI in the SEP group (Fig. 2; Table S2, supporting
information).
Clinical outcomes (International Society for Cardiovascular
Surgery scores)
At 12 months after treatment in the PTA group,
37 (71 per cent) of 52 patients had improved (mild
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Fig. 2 Box-and-whisker plots representing selected outcomes for the clinical indicators of lower limb ischaemia in trial participants: a
intermittent claudication distance; b maximum walking distance; c patient-reported walking distance; d postexercise ankle : brachial
pressure index (ABPI). Full details of all clinical outcomes can be found in Table S2 (supporting information). Median values,
interquartile ranges (i.q.r.) and up to 1·5 times the i.q.r. (excluding outliers,
°
) are denoted by horizontal bars, boxes and whiskers
respectively. PTA, percutaneous transluminal angioplasty; SEP supervised exercise programme. There were statistically significant
improvements in all groups, but no significant differences between the groups except for postexercise ABPI (P = 0·002, Kruskal–Wallis
ANOVA) (Table 3)
improvement, 16 (31 per cent); moderate improvement,
16 (31 per cent); marked improvement, 5 (10 per cent)),
nine (17 per cent) demonstrated no change, and six
(12 per cent) had deteriorated (mild deterioration, 3
(6 per cent); moderate deterioration, 3 (6 per cent)).
At 12 months after treatment in the SEP group,
32 (70 per cent) of 46 patients had improved (mild
improvement, 19 (41 per cent); moderate improvement,
10 (22 per cent), marked improvement, 3 (7 per cent)),
six (13 per cent) demonstrated no change, and eight
(17 per cent) had deteriorated (mild deterioration, 5
(11 per cent); moderate deterioration, 3 (7 per cent)).
At 12 months in the PTA plus SEP group, 40
patients (85 per cent) had improved (mild improvement,
18 (38 per cent); moderate improvement, 20 (43 per cent);
marked improvement, 2 (4 per cent)) after treatment, and
seven (15 per cent) demonstrated no change. No patient in
this treatment arm reported any deterioration at 1 year.
There were no significant differences in outcomes
between the groups (P = 0·211, χ2 for trend).
Quality-of-life indicators (Fig. 3; Table S3, supporting
information)
Patients in the PTA group had statistically significant
improvements in all SF-36 domains and the VascuQol
score, except in the vitality (V) domain of SF-36.
Patients in the SEP group had statistically significant
improvements in VascuQol score and in the PF,
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Fig. 3 Box-and-whisker plots representing selected quality-of-life (QoL) outcome indicators for trial participants: a general health, b
physical function and c vitality Short Form 36 (SF-36) domain scores, and d King’s College Vascular Quality of Life (VascuQol)
scores. Full details of all QoL outcomes can be found in Table S3 (supporting information). Median values, interquartile ranges (i.q.r.)
and up to 1·5 times the i.q.r. (excluding outliers,
°
) are denoted by horizontal bars, boxes and whiskers respectively. PTA, percutaneous
transluminal angioplasty; SEP supervised exercise programme. There were statistically significant improvements in all groups, but no
significant differences between the groups (Table 3)
role limitation emotional (RE) and mental health
(MH) domains. However, no statistically significant
improvements were seen in the domains for role limitation
physical (RP), bodily pain (BP), general health (GH), V
and social functioning (SF).
Patients in the PTA plus SEP group had statistically
significant improvements in the VascuQol scores and
SF-36 domains for PF, BP and SF. No statistically
significant improvements were observed in the domain
scores for RP, GH, V, RE and MH.
Intergroup analyses
PTA and PTA plus SEP resulted in a significantly
higher median postexercise ABPI compared with SEP
alone at 12 months (P = 0·002). However, there were
no statistically significant differences between the three
treatment arms in any other clinical indicator, ISCVS
outcomes or QoL indicators at 12 months (Table 3).
Restenosis and reintervention rates
Duplex ultrasonography was performed at 3 months after
intervention in 57 (95 per cent) of the 60 patients in the
PTA group and in 48 (83 per cent) of the 58 in the
PTA plus SEP group. Significant restenosis (defined by
a doubling of peak systolic velocity as standard) was seen
in seven (12 per cent) and four (8 per cent) respectively of
the scanned patients (P = 0·751). At the final 12-month
follow-up, duplex imaging was done in 35 (67 per cent) of
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Table 3 Summary statistics for intergroup comparison of clinical
and quality-of-life indicators at 12 months
P*
Clinical indicators
ABPI
Resting 0·093
After exercise 0·002
Intermittent claudication distance 0·484
Maximum walking distance 0·259
Patient-reported walking distance 0·801
Quality-of-life indicators
Short Form 36
Physical function 0·758
Role limitation physical 0·865
Bodily pain 0·284
General health 0·839
Vitality 0·800
Social function 0·701
Role limitation emotional 0·988
Mental health 0·144
VascuQol 0·906
ABPI, ankle : brachial pressure index; VascuQol, King’s College Vascular
Quality of Life questionnaire. *Kruskal–Wallis ANOVA.
52 patients in the PTA group and in 34 (72 per cent) of 47
in the PTA plus SEP group. Restenosis was identified in
24 (69 per cent) and 23 (68 per cent) respectively of these
patients (P = 0·799).
Nine (15 per cent) of the 60 patients in the PTA group
required reintervention and six (10 per cent) of 60 in the
SEP group needed an intervention within 12 months;
however, none of the patients in PTA plus SEP group
required any reintervention. This difference was not
statistically significant (P = 0·065).
Discussion
Treatment of IC due to femoropopliteal atherosclerosis has
always posed a challenge. AlthoughTASC II provides some
guidelines11, there is no established standard treatment.
BMT is initiated in all patients, followed by either SEP
or PTA depending on the nature of the lesion, severity
of symptoms and suitability for treatment2,4,8,11. Both
SEP and PTA have been shown to improve clinical and
QoL outcomes when compared to conservative medical
treatment and unsupervised exercise14,19,22–28. Previous
trials comparing PTA and SEP were underpowered and
hence inconclusive12,13,15,27. Furthermore, to date, only
one randomized trial has described the combined effect
of PTA, SEP and BMT on clinical and generic QoL
indicators compared with SEP and BMT29.
Previously, a statistically significant improvement in
clinical indicators was reported at 3 months, with patients
in the PTA plus SEP group performing better than those
having either PTA or SEP alone30. This initial advantage
was not sustained at 12 months. Generally, patients who
had PTA demonstrated an immediate improvement in all
indicators at 1 month after intervention, but with some
deterioration at 3 and 6 months, followed by improvement
again at 12 months, probably due to reintervention.
Patients having SEP lacked this immediate response and
showed a more gradual trend of improvement that peaked
at 6–12 months, with some deterioration at 12 months in
some parameters. Patients who had PTA plus SEP had a
combination of the twophenomena: an initial improvement
after PTA followed by a sustained improvement lasting
throughout the year.
Improvement in ABPI as a result of angioplasty in the
PTA and PTA plus SEP groups followed the general trend
described previously. However, improvement in resting
ABPI after SEP was a novel finding and contradicts
previous evidence13,14,29. This change was seen as early
as 3 months and was sustained at 1 year. Remodelling of
the collateral circulation in response to ongoing ischaemia
and opening up of preformed collaterals with SEP are likely
explanations30. ICD and MWD are more reliable clinical
indicators of the severity of leg ischaemia than ABPI11.
Improvements in ICD and MWD had a slightly different
trend from ABPI: the results were very variable after PTA,
whereas patients who had SEP demonstrated a gradual
improvement in ICD up to 6 months with continuing
improvement in MWD at 12 months.
The lack of a statistically significant difference between
the treatments at 12 months in ICD and MWD can be
explained by the ceiling effect as a consequence of capping
the treadmill test at 5 min (215 m). Future studies could
increase the time cap to 10 or 15 min.
The subjective nature of PRWD limits its value, with a
relatively poor correlation with other clinical and QoL
domains17. Recent studies have demonstrated a better
correlation between PRWD and generic QoL indices31,
providing some evidence for its value in clinical trials. In the
present study, intragroup and intergroup trends for PRWD
were similar to other clinical indicators, demonstrating its
sensitivity to change and value as a subjective indicator of
leg ischaemia.
Although no statistically significant difference was
observed between the three treatments after 12 months,
the fact that no patient in the PTA plus SEP group
deteriorated or required reintervention by 12 months is
clinically significant. The restenosis rates in PTA and PTA
plus SEP groups were comparable and similar to previously
published values10,28. Thus, combining SEP with PTA
did not reduce the risk of restenosis, but prevented it
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from becoming symptomatic, leading to sustained clinical
improvement.
The primary aim of treatment for IC is improvement
in QoL3,7. Correlation between improvement in clinical
and QoL indicators for patients with IC is moderate
at best16,17,31, with relatively better results for disease-
specific measures20. Previous studies have reported QoL as
secondary outcome with sample size calculation performed
primarily for clinical outcomes13,29. The present study
was powered for QoL parameters as the primary outcome
measures.
Improvement observed in the disease-specific Vas-
cuQol and PF domain scores of generic SF-36 across
all treatment groups is in accordance with previous
evidence12,29,32. In addition, improvement in the BP
domain of the SF-36 after treatments involving angio-
plasty is understandable. However, improvements seen in
GH, SF, RE and MH domains in the PTA only group
are not consistent with previous studies13,29,32,33. Possible
explanations include the effect of reinterventions on QoL
scores, low baseline in certain domains, the semiordinal
nature of SF-36 scoring, or chance. Similarly, improve-
ment in SF-36 REandMHdomains after SEP contradicts
previous evidence19. ThePTAplus SEP groupwas the only
one with results consistent with available evidence12,13,19.
There are a few limitations of the present study. Only
patients with symptomatic, unilateral femoropopliteal
arterial disease were included; this represents only
15–20 per cent of patients with IC1,6, resulting in exclusion
of a large number of patients with bilateral ormixed arterial
disease. However, this was necessary from a scientific point
of view to reduce the influence of confounders, and to
provide a robust answer to the treatment controversy in
this group. In addition, the time cap of 5 min for the fixed-
load treadmill test had a limiting effect on the interpretation
of results for ICD and MWD. Finally, the loss to follow-
up was more than anticipated in the SEP and PTA plus
SEP groups. This was mainly due to the withdrawal of
patients from the hospital-based SEP, owing to lack of
hospital transport and long distances between patients’
homes and hospital. Provision of a community-based SEP
could address this issue in future.
This trial demonstrated no statistically significant
difference between the three treatments after 1 year.
PTA was associated with a high incidence of restenosis,
adding both the costs of reintervention and the potential
for complications10. SEP provided an equally effective
alternative, with relatively lower costs19; however, patients
needed commitment to the programme (3 times a week
for 3 months) for an optimal outcome11,23. Currently,
these services are not provided in the community.
Combining the two treatments had a sustained effect,
while reducing the rate (and cost) of reinterventions, but
still with the difficulties associated with a hospital-based
SEP. The provision of this service in the community to
reduce patients’ time and travelling costs, while delivering
a clinically effective treatment, would be optimal. A
full economic analysis of the cost-effectiveness of these
treatments will help to make rational recommendations.
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